marked.bio

Company

Syndax Pharmaceuticals

3 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

revumenib 3

Trials

3 of 4 trials shown

  1. Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

    Recruiting Phase 3 Syndax Pharmaceuticals Started 2025Primary completion 2029-06 NCT07211958

    revumenib FDAIntensive Chemotherapy Regimen

    Presence of an NPM1 mutation.

    NPM1 mutationAcute Myeloid Leukemias

  2. A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

    Recruiting Phase 1/2 Syndax Pharmaceuticals Started 2019Primary completion 2027-12 NCT04065399

    revumenib FDAcobicistat

    …Version 3.2020), or acute leukemia harboring KMT2A rearrangement, NUP98 rearrangement, or NPM1 mutation that have detectable disease in the bone marrow.

    NPM1 mutationAcute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia

  3. A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

    Active, not recruiting Phase 1 Syndax Pharmaceuticals Started 2024Primary completion 2027-02 NCT06226571

    revumenib FDAChemotherapy RegimenHiDAC

    KMT2Ar, NPM1m, or NUP98r mutations identified by local laboratory prior to the first dose of revumenib.

    NPM1 mutationAcute Myeloid Leukemias